These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27334605)

  • 1. Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations.
    Angmo D; Wadhwani M; Velpandian T; Kotnal A; Sihota R; Dada T
    Int Ophthalmol; 2017 Apr; 37(2):423-428. PubMed ID: 27334605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The physical properties of generic latanoprost ophthalmic solutions are not identical.
    Kolko M; Koch Jensen P
    Acta Ophthalmol; 2017 Jun; 95(4):370-373. PubMed ID: 28229536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in Number of Doses, Bottle Volume, and Calculated Yearly Cost of Generic and Branded Latanoprost for Glaucoma.
    Queen JH; Feldman RM; Lee DA
    Am J Ophthalmol; 2016 Mar; 163():70-74.e1. PubMed ID: 26596398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Physical Properties of Generic and Branded Travoprost Formulations.
    Wadhwani M; Mishra SK; Angmo D; Velpandian T; Sihota R; Kotnala A; Bhartiya S; Dada T
    J Curr Glaucoma Pract; 2016; 10(2):49-55. PubMed ID: 27536047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of latanoprost in generic formulations using controlled degradation and patient usage simulation studies.
    Velpandian T; Kotnala A; Halder N; Ravi AK; Archunan V; Sihota R
    Curr Eye Res; 2015 May; 40(6):561-71. PubMed ID: 25494824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study comparing Xalatan
    Diagourtas A; Kagelaris K; Oikonomakis K; Droulias A; Kokolakis N; Papaconstantinou D
    Eur J Ophthalmol; 2018 Jul; 28(4):378-384. PubMed ID: 29952663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension.
    Narayanaswamy A; Neog A; Baskaran M; George R; Lingam V; Desai C; Rajadhyaksha V
    Indian J Ophthalmol; 2007; 55(2):127-31. PubMed ID: 17322603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
    Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latanoprost 0.005% test formulation is as effective as Xalatan® in patients with ocular hypertension and primary open-angle glaucoma.
    Allaire C; Dietrich A; Allmeier H; Grundmane I; Mazur-Piotrowska G; Neshev P; Kahle G
    Eur J Ophthalmol; 2012; 22(1):19-27. PubMed ID: 22167539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment.
    Stjernschantz J; Selén G; Astin M; Resul B
    Prog Retin Eye Res; 2000 Jul; 19(4):459-96. PubMed ID: 10785618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride.
    Wong TT; Aung T; Ho CL
    Clin Exp Ophthalmol; 2018 Dec; 46(9):1028-1034. PubMed ID: 29802759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of intraocular pressure in glaucoma subjects treated with Xalatan versus generic latanoprost.
    Egan P; Harris A; Siesky B; Abrams-Tobe L; Gerber AL; Park J; Holland S; Kim NJ; Januleviciene I
    Acta Ophthalmol; 2014 Aug; 92(5):e415-6. PubMed ID: 24373426
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of latanoprost when stored at room temperature.
    Mochizuki H; Itakura H; Takamatsu M; Kiuchi Y
    Hiroshima J Med Sci; 2008 Jun; 57(2):69-72. PubMed ID: 18717189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension.
    Eveleth D; Starita C; Tressler C
    BMC Ophthalmol; 2012 May; 12():9. PubMed ID: 22607109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance.
    Rodriguez-Aller M; Guinchard S; Guillarme D; Pupier M; Jeannerat D; Rivara-Minten E; Veuthey JL; Gurny R
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):203-14. PubMed ID: 25960331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status of prostaglandin therapy: latanoprost and unoprostone.
    Susanna R; Chew P; Kitazawa Y
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S97-104. PubMed ID: 12204705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension.
    Aptel F; Choudhry R; Stalmans I
    Curr Med Res Opin; 2016 Aug; 32(8):1457-63. PubMed ID: 27310103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
    Schachar RA; Raber S; Courtney R; Zhang M
    Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: a patient-use study.
    Paolera MD; Kasahara N; Umbelino CC; Walt JG
    BMC Ophthalmol; 2008 Jun; 8():11. PubMed ID: 18547433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials.
    Fechtner RD; Airaksinen PJ; Getson AJ; Lines CR; Adamsons IA;
    Acta Ophthalmol Scand; 2004 Feb; 82(1):42-8. PubMed ID: 14982045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.